The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces September 2011 Investor Conference Presentations

Wednesday, August 31, 2011

Regeneron Announces September 2011 Investor Conference Presentations09:30 EDT Wednesday, August 31, 2011TARRYTOWN, N.Y., Aug. 31, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:Citi's 6th Annual Biotech Day panel discussion on the topic "Eye Can See Clearly Now the Rain is Gone: New Drugs for Wet AMD" at 9:00 a.m. Eastern Time on Wednesday, September 7, 2011Morgan Stanley Global Healthcare Conference at 2:45 p.m. Eastern Time on Tuesday, September 13, 2011UBS Global Life Sciences Conference at 9:30 a.m. Eastern Time on Monday, September 19, 2011   The sessions may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.  Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.345.7799 914.345.7640michael.aberman@regeneron.competer.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.